HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
Many patients fail to respond to T cell based immunotherapies. Here, the authors, through a high-throughput screening, identify HSP90 inhibitors as a class of preferred drugs for treatment combination with immunotherapy.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017-09-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-017-00449-z |
| id |
doaj-51b2a4e16a0b435cabee2477f3975980 |
|---|---|
| record_format |
Article |
| spelling |
doaj-51b2a4e16a0b435cabee2477f39759802021-05-11T07:33:42ZengNature Publishing GroupNature Communications2041-17232017-09-01811810.1038/s41467-017-00449-zHSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genesRina M. Mbofung0Jodi A. McKenzie1Shruti Malu2Min Zhang3Weiyi Peng4Chengwen Liu5Isere Kuiatse6Trang Tieu7Leila Williams8Seram Devi9Emily Ashkin10Chunyu Xu11Lu Huang12Minying Zhang13Amjad H. Talukder14Satyendra C. Tripathi15Hiep Khong16Nikunj Satani17Florian L. Muller18Jason Roszik19Timothy Heffernan20James P. Allison21Gregory Lizee22Sam M. Hanash23David Proia24Rodabe Amaria25R. Eric Davis26Patrick Hwu27Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Lymphoma/Myeloma Unit 903, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Lymphoma/Myeloma Unit 903, The University of Texas MD Anderson Cancer CenterInstitute for Applied Cancer Sciences Unit 1956, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Clinical Cancer Prevention Unit 1013, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterCancer Imaging Systems Unit 1907, The University of Texas MD Anderson Cancer CenterCancer Imaging Systems Unit 1907, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterInstitute for Applied Cancer Sciences Unit 1956, The University of Texas MD Anderson Cancer CenterDepartment of Immunology Unit 901, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Clinical Cancer Prevention Unit 1013, The University of Texas MD Anderson Cancer CenterSynta Pharmaceuticals Inc.Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterDepartment of Lymphoma/Myeloma Unit 903, The University of Texas MD Anderson Cancer CenterDepartment of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer CenterMany patients fail to respond to T cell based immunotherapies. Here, the authors, through a high-throughput screening, identify HSP90 inhibitors as a class of preferred drugs for treatment combination with immunotherapy.https://doi.org/10.1038/s41467-017-00449-z |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Rina M. Mbofung Jodi A. McKenzie Shruti Malu Min Zhang Weiyi Peng Chengwen Liu Isere Kuiatse Trang Tieu Leila Williams Seram Devi Emily Ashkin Chunyu Xu Lu Huang Minying Zhang Amjad H. Talukder Satyendra C. Tripathi Hiep Khong Nikunj Satani Florian L. Muller Jason Roszik Timothy Heffernan James P. Allison Gregory Lizee Sam M. Hanash David Proia Rodabe Amaria R. Eric Davis Patrick Hwu |
| spellingShingle |
Rina M. Mbofung Jodi A. McKenzie Shruti Malu Min Zhang Weiyi Peng Chengwen Liu Isere Kuiatse Trang Tieu Leila Williams Seram Devi Emily Ashkin Chunyu Xu Lu Huang Minying Zhang Amjad H. Talukder Satyendra C. Tripathi Hiep Khong Nikunj Satani Florian L. Muller Jason Roszik Timothy Heffernan James P. Allison Gregory Lizee Sam M. Hanash David Proia Rodabe Amaria R. Eric Davis Patrick Hwu HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes Nature Communications |
| author_facet |
Rina M. Mbofung Jodi A. McKenzie Shruti Malu Min Zhang Weiyi Peng Chengwen Liu Isere Kuiatse Trang Tieu Leila Williams Seram Devi Emily Ashkin Chunyu Xu Lu Huang Minying Zhang Amjad H. Talukder Satyendra C. Tripathi Hiep Khong Nikunj Satani Florian L. Muller Jason Roszik Timothy Heffernan James P. Allison Gregory Lizee Sam M. Hanash David Proia Rodabe Amaria R. Eric Davis Patrick Hwu |
| author_sort |
Rina M. Mbofung |
| title |
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes |
| title_short |
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes |
| title_full |
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes |
| title_fullStr |
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes |
| title_full_unstemmed |
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes |
| title_sort |
hsp90 inhibition enhances cancer immunotherapy by upregulating interferon response genes |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2017-09-01 |
| description |
Many patients fail to respond to T cell based immunotherapies. Here, the authors, through a high-throughput screening, identify HSP90 inhibitors as a class of preferred drugs for treatment combination with immunotherapy. |
| url |
https://doi.org/10.1038/s41467-017-00449-z |
| work_keys_str_mv |
AT rinammbofung hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT jodiamckenzie hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT shrutimalu hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT minzhang hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT weiyipeng hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT chengwenliu hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT iserekuiatse hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT trangtieu hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT leilawilliams hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT seramdevi hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT emilyashkin hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT chunyuxu hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT luhuang hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT minyingzhang hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT amjadhtalukder hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT satyendractripathi hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT hiepkhong hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT nikunjsatani hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT florianlmuller hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT jasonroszik hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT timothyheffernan hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT jamespallison hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT gregorylizee hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT sammhanash hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT davidproia hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT rodabeamaria hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT rericdavis hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes AT patrickhwu hsp90inhibitionenhancescancerimmunotherapybyupregulatinginterferonresponsegenes |
| _version_ |
1721451998021156864 |